Aaron Vedell Martin

US Patent:

20220411479, Dec 29, 2022

Filed:

Oct 30, 2020

Appl. No.:

17/773456

Inventors:

- Durham NC, US
Aaron Martin - Carrboro NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C07K 14/725
A61K 35/17
A61K 45/06
A61P 35/00

Abstract:

Provided herein are compositions and methods for the treatment of a disease, such as cancer, using a chimeric antigen receptor or genetically-modified cells comprising a chimeric antigen receptor having specificity for CD20. The invention provides polynucleotides encoding such chimeric antigen receptors, and genetically-modified cells comprising such chimeric antigen receptors. Also provided are methods for making such genetically-modified cells and pharmaceutical compositions comprising the same. The invention further provides methods for treating a disease (e.g., cancer) in a subject by administering such genetically-modified cells or compositions. The main embodiments concern CARs with an scFv specific for CD20, the hinge and transmembrane domains from CD8, the costimulatory cytoplasmic or signalling domain from co-stimulatory molecules Novell (N1) or Novel6 (N6) and the CD3zeta intracellular signaling domain.

US Patent:

20220228115, Jul 21, 2022

Filed:

Apr 4, 2022

Appl. No.:

17/712864

Inventors:

- Durham NC, US
Aaron Martin - Carrboro NC, US
Derek Jantz - Durham NC, US
Clayton Beard - Durham NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 5/0783
C07K 14/725
C07K 14/74
C07K 16/28
C12N 15/113

Abstract:

The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclosure further relates to nucleic acids, DNA constructs, vectors, pharmaceutical compositions, genetically-modified cells, and methods of treatment that utilize the nucleic acid molecules of the invention.

US Patent:

20220204994, Jun 30, 2022

Filed:

Apr 3, 2020

Appl. No.:

17/601415

Inventors:

- Durham NC, US
Aaron Martin - Carrboro NC, US
Melissa Samo - Raleigh NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C12N 15/88
C12N 5/0783
C12N 15/62

Abstract:

The present disclosure provides methods for preparing a population of genetically-modified immune cells. The methods include contacting a population of immune cells with lipid nanoparticles in the presence of an apolipoprotein. The lipid nanoparticles include mRNA encoding an engineered nuclease having specificity for a recognition sequence in the genome of the immune cells. The mRNA is delivered into the immune cells and the engineered nuclease is expressed, generating a cleavage site at the recognition sequence. Further provided are populations of genetic ally-modified immune cells produced according to the disclosed methods, pharmaceutical compositions containing such cells, and methods of treating diseases with the genetically-modified immune cells.

US Patent:

20230036065, Feb 2, 2023

Filed:

Dec 3, 2020

Appl. No.:

17/782607

Inventors:

- Durham NC, US
Derek Jantz - Durham NC, US
Aaron Martin - Carrboro NC, US
Daniel T. MacLeod - La Jolla CA, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

A61K 35/17
A61K 39/395
A61K 31/664
A61K 31/7076
C07K 16/28
A61K 38/17
A61P 35/00
A61P 35/02

Abstract:

The present invention encompasses methods of cancer immunotherapy, and particularly methods of allogeneic cellular immunotherapy, using particular lymphodepletion regimens in combination with particular populations of chimeric antigen receptor T cells expressing anti CD19 CAR PBCAR0191, anti CD20 CAR PBCAR20A or anti BCMA CAR PBCAR269A.

US Patent:

20210032664, Feb 4, 2021

Filed:

Oct 19, 2020

Appl. No.:

17/074135

Inventors:

- Durham NC, US
Christina Pham - Durham NC, US
Aaron Martin - Carrboro NC, US
Derek Jantz - Durham NC, US
James Jefferson Smith - Morrisville NC, US
Michael G. Nicholson - Chapel Hill NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 15/90
C12N 9/22
A61K 47/69
A61K 35/17
C12N 15/52
C12N 15/62

Abstract:

Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human beta-2 microglobulin gene. The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified T cells having reduced cell-surface expression of beta-2 microglobulin.

US Patent:

20200399346, Dec 24, 2020

Filed:

Sep 9, 2020

Appl. No.:

17/016016

Inventors:

- Durham NC, US
Aaron Martin - Carrboro NC, US
Daniel T. MacLeod - Durham NC, US

Assignee:

Precision BioSciences, Inc. - Durham NC

International Classification:

C07K 14/715
C07K 14/725
C07K 14/705
C07K 16/28
A61P 35/00
A61K 35/17
C12N 5/0783
C12N 7/00
C12N 9/90

Abstract:

The present disclosure provides novel co-stimulatory domains useful in genetically-modified cells to promote cell proliferation and/or promote cytokine secretion after antigen recognition. For example, disclosed herein are genetically-modified cells comprising a chimeric antigen receptor or an inducible regulatory construct incorporating the co-stimulatory domains disclosed herein. Also disclosed herein are plasmids and viral vectors comprising a nucleic acid sequence encoding the co-stimulatory domains, and methods of administering compositions comprising the novel co-stimulatory domains to subjects in order to reduce the symptoms, progression, or occurrence of disease, such as cancer.

US Patent:

20200339952, Oct 29, 2020

Filed:

Jul 13, 2020

Appl. No.:

16/927452

Inventors:

- Durham NC, US
Aaron Martin - Carrboro NC, US
Derek Jantz - Durham NC, US
Clayton Beard - Durham NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 5/0783
C07K 14/725
C07K 14/74
C07K 16/28
C12N 15/113

Abstract:

The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclosure further relates to nucleic acids, DNA constructs, vectors, pharmaceutical compositions, genetically-modified cells, and methods of treatment that utilize the nucleic acid molecules of the invention.

US Patent:

20200063102, Feb 27, 2020

Filed:

Nov 8, 2019

Appl. No.:

16/678600

Inventors:

- Durham NC, US
Aaron Martin - Carrboro NC, US
Derek Jantz - Durham NC, US
Clayton Beard - Durham NC, US

Assignee:

Precision Biosciences, Inc. - Durham NC

International Classification:

C12N 5/0783
C07K 14/725
C07K 14/74
C12N 15/113
C07K 16/28

Abstract:

The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclosure further relates to nucleic acids, DNA constructs, vectors, pharmaceutical compositions, genetically-modified cells, and methods of treatment that utilize the nucleic acid molecules of the invention.